HeartSciences Inc. — fact timeline

HeartSciences Inc. shareholders approved Adjournment of the Annual Meeting to Solicit Additional Proxies if Necessary at the 2026-04-30 meeting.

“Proposal 5: Adjournment Proposal The Company’s shareholders approved the one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies if there are insufficient votes to approve any of the proposals at the time of the Annual Meeting by voting as follows: For Against Abstain 1,784,662 185,241 3,958”

HeartSciences Inc. shareholders approved Ratification of Appointment of Haskell & White LLP as Independent Registered Public Accounting Firm at the 2026-04-30 meeting.

“Proposal 4: Auditor Ratification Proposal The Company’s shareholders ratified the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2026 by voting as follows: For Against Abstain 1,872,912 91,205 9,745”

HeartSciences Inc. shareholders rejected Amendment of the Company’s Certificate of Formation to Provide for Exculpation of Officers at the 2026-04-30 meeting.

“Proposal 3: Amendment of the Company’s Certificate of Formation to Provide for Exculpation of Officers of the Company The Company’s shareholders voted as follows with respect to the Company’s proposed amendment of its Amended and Restated Certificate of Formation to authorize the exculpation of officers of the Company in limited circumstances as allowed by Texas law: For Against Abstained Broker Non-Votes 542,609 133,919 9,050 1,288,285”

HeartSciences Inc. shareholders approved Amendment of the Company’s 2023 Employee Stock Purchase Plan at the 2026-04-30 meeting.

“Proposal 2: Amendment of the Company’s 2023 Employee Stock Purchase Plan The Company’s shareholders approved an increase of the number of shares of the Company’s common stock reserved for issuance under the Company’s 2023 Equity Incentive Plan (as amended, the “Plan”) to 1,250,000 shares, plus such number of shares of common stock, which is equal to the lesser of (i) 25% of the total number of shares of all classes of common stock and the Company’s preferred stock, $0.001 par value per share, as converted to common stock, outstanding on the last day of each the immediately preceding fiscal year, and (ii) a lesser number of shares of our common stock determined by the Administrator (as defined in the Plan), by voting as follows: For Against Abstained Broker Non-Votes 359,995 323,187 2,395 1,288,266”

HeartSciences Inc. shareholders approved Election of Directors at the 2026-04-30 meeting.

“Proposal 1: Election of Directors The following one Class III nominee will serve for a three-year term expiring on the date of the Company’s Annual Meeting of Shareholders to be held for its fiscal year ending April 30, 2028 or until his successor is duly elected or his earlier resignation or removal. The voting with respect to the election of directors was as follows: Election of Directors For Withheld Broker Non-Votes Andrew Simpson 577,840 107,738 1,288,285”

HeartSciences Inc. reported fiscal third quarter ended January 31, 2026 results: revenue no meaningful revenue.

“HeartSciences reported no meaningful revenue for FQ3 2026”

HeartSciences Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $3,605,000 (effective 2026-01-13).

“On January 13, 2026, HeartSciences Inc. (the “Company” entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Streeterville Capital, LLC, an institutional investor (“Streeterville”), pursuant to which Streeterville purchased from the Company an unsecured promissory note in the amount of $3,605,000”

HeartSciences Inc. incurred senior notes of $3,605,000 with Streeterville Capital, LLC at 12% per annum maturing 18 months after its issuance date.

“On January 13, 2026, HeartSciences Inc. (the “Company” entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Streeterville Capital, LLC, an institutional investor (“Streeterville”), pursuant to which Streeterville purchased from the Company an unsecured promissory note in the amount of $3,605,000 (the “Note”)”

HeartSciences Inc. amended loan of $500,000 with Front Range Ventures LLC at 12% per annum maturing September 30, 2026.

“Loan Agreement, the No. 1 Amendment, the No. 2 Amendment, the No. 3 Amendment, the No. 4 Amendment and the No. 5 Amendment, the “Loan Agreement”), for the Company to borrow $500,000 from Front Range Ventures LLC (“FRV”) as evidenced by a secured, non-convertible promissory note, dated April 24, 2020, as amended by the Amended and Restated Secured Promissory”

HeartSciences Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“osed. As previously disclosed in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on March 21, 2025, the Company previously received a letter from the Staff indicating that the Company was not in compliance with the requirements of Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity (the “Minimum Stockholders’ Equity Requirement”), and the Company did not otherwise meet the alternative requirements of market value of listed securiti”

HeartSciences Inc.: Amended Bylaws to add jury trial waiver for internal entity claims, adopt ownership threshold for derivative proceedings, and clarify exclusive forum provision (effective 2025-06-27).

“On June 27, 2025, in connection with certain recent changes to the Texas Business Organizations Code (“TBOC”) and in light of Texas law, the Board of Directors of HeartSciences Inc. (the “Company”) adopted certain amendments to the Company’s Bylaws (the “Bylaws”) in order to: (i) add a new section to provide for a jury trial waiver for “internal entity claims” as defined in the TBOC; (ii) add a new section to adopt an ownership threshold requiring any shareholder or group of shareholders to hold shares of common stock sufficient to meet an ownership threshold of at least 3% of the Company’s issued and outstanding shares in order to institute or maintain a derivative proceeding; and (iii) make technical revisions to clarify the scope of the exclusive forum provision.”

HeartSciences Inc.: Filed Certificate of Designations for Series D Convertible Preferred Stock, designating 4,285,714 shares as Series D Preferred Stock, effective May 21, 2025 (effective 2025-05-21).

“On May 28, 2025, the Company was notified by the Secretary of State of the State of Texas (the “Texas Secretary of State”) that the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Stock (the “Certificate of Designations”) was filed with the Texas Secretary of State, effective as of May 21, 2025, designating 4,285,714 shares of the Company’s preferred stock, $0.001 par value per share, as the Company’s Series D Convertible Preferred Stock, $0.001 par value per share (the “Series D Preferred Stock”).”

HeartSciences Inc.: The Company filed a Certificate of Designations with the Texas Secretary of State designating 4,285,714 shares of preferred stock as Series D Convertible Preferred Stock, with terms including conversion rights, liquidation preference, ranking, and no voting rights (effective 2025-05-21).

“On May 21, 2025, the Company submitted the Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Stock (the “Certificate of Designations”) with the Secretary of State of the State of Texas (the “Texas Secretary of State”) designating 4,285,714 shares of the Company’s preferred stock as “Series D Convertible Preferred Stock”.”

HeartSciences Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 19, 2025, HeartSciences Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its quarterly report for the period ended January 31, 2025, the Company reported stockholders’ equity of $1,786,689, and, as of March 19, 2025, the Company did not meet the alternatives of market value of listed s”

HeartSciences Inc.: Company amended its Amended and Restated Certificate of Formation to change its corporate name to HeartSciences Inc (effective 2024-10-11).

“On October 11, 2024, the Company changed its corporate name to HeartSciences Inc. pursuant to the Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Formation, filed with the Secretary of State of the State of Texas on the same date (the “Name Change”).”

HeartSciences Inc.: Certificate of Amendment to Amended and Restated Certificate of Formation to effect a 1-for-100 reverse stock split of Common Stock and Warrants (effective 2024-05-06).

“the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Formation (the “Certificate of Amendment”) with the Secretary of State of Texas to, among other things, effect on the corporate level a one-for-one hundred reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.001 par value per share (the “Common Stock”), and also to effect a one-for-one hundred Reverse Stock Split of the Company’s warrants (the “Warrants”).”

HeartSciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

“May 9, 2024, the Company received a staff determination from Nasdaq to delist the Company’s securities from the Nasdaq Capital Market (the “Staff Determination”). The Staff Determination was issued because, as of May 8, 2024, the Company’s Common Stock had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). The Company may appeal the Staff Determination to a Nasdaq Hearings Panel (the “Panel”) by filing a hearing request wit”

HeartSciences Inc. reported third quarter fiscal 2024 ended January 31, 2024 results: revenue There were no significant revenues in the third quarter fiscal 2024..

“HeartSciences Reports Third Quarter Fiscal 2024 Financial Results Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc . d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.”

HeartSciences Inc. shareholders approved Proposal 7: Quorum Reduction Proposal at the 2024-02-15 meeting.

“The Company’s shareholders approved an amendment to the Company's Certificate of Formation to decrease the number of shares of the Company’s Common Stock needed to establish a quorum for meetings of the Company’s shareholders by voting as follows: For Against Abstain Broker Non-Votes 27,172,440 1,298,890 362,117 1,015,919”

HeartSciences Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).

“January 30, 2024, the Company received a letter from Nasdaq advising that the Company had been granted an additional 180-day extension to July 29, 2024, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If the Company does not regain compliance within the allotted compliance period, Nasdaq staff will provide notice that the Company’s Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The Company will continue to monitor the closing bid price of it”

HeartSciences Inc. shareholders approved Adjournment Proposal at the 2024-01-17 meeting.

“Proposal 8: Adjournment Proposal The Company’s shareholders approved the one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies if there are insufficient votes to approve any of the proposals at the time of the Annual Meeting by voting as follows: For Against Abstain 28,078,902 759,077 461,197”

HeartSciences Inc. shareholders voted on Quorum Reduction Proposal at the 2024-01-17 meeting.

“Proposal 7: Quorum Reduction Proposal The Company did not receive sufficient proxies from shareholders to approve an amendment to the Company's Certificate of Formation to decrease the number of shares of the Company’s Common Stock needed to establish a quorum for meetings of the Company’s shareholders. Pursuant to the approval of Proposal 8 (below), the Company adjourned the Annual Meeting with respect to Proposal 7. During the period of the adjournment, the Company will continue to solicit votes from its shareholders with respect to Proposal 7. The voting at the time of the Annual Meeting was as follows: For Against Abstain Broker Non-Votes 26,500,809 1,415,185 367,263 1,015,920”

HeartSciences Inc. shareholders approved ELOC Issuance Proposal at the 2024-01-17 meeting.

“Proposal 2: ELOC Issuance Proposal The Company’s shareholders approved the full issuance of shares of the Company’s Common Stock issuable by the Company pursuant to its purchase agreement, dated as of March 10, 2023, with Lincoln Park Capital Fund, LLC (the “ELOC Issuance Proposal”) for purposes of complying with Nasdaq Listing Rule 5635(d), by voting as follows: For Against Abstain Broker Non-Votes 22,113,326 928,881 212,533 6,044,437”

HeartSciences Inc. shareholders approved Proposal to Approve the Company’s 2023 Employee Stock Purchase Plan, as Amended at the 2024-01-17 meeting.

“Proposal 3: Proposal to Approve the Company’s 2023 Employee Stock Purchase Plan, as Amended The Company’s shareholders approved the Company’s 2023 Equity Incentive Plan, as amended, by voting as follows: For Against Abstain Broker Non-Votes 16,969,611 5,682,886 602,244 6,044,437”

HeartSciences Inc. shareholders approved Auditor Ratification Proposal at the 2024-01-17 meeting.

“Proposal 4: Auditor Ratification Proposal The Company’s shareholders ratified the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024 by voting as follows: For Against Abstain 28,840,623 207,972 250,581”

HeartSciences Inc. shareholders approved Name Change Proposal at the 2024-01-17 meeting.

“Proposal 6: Name Change Proposal The Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Formation to change the Company’s corporate name from “Heart Test Laboratories, Inc.” to “HeartSciences Inc.” by voting as follows: For Against Abstain 28,852,380 239,552 207,243”

HeartSciences Inc. shareholders approved Reverse Stock Split Proposal at the 2024-01-17 meeting.

“Proposal 5: Reverse Stock Split Proposal The Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Formation (the “Certificate of Formation”) to effect, at the sole discretion of the Company’s Board of Directors, a reverse stock split of all outstanding shares of the Company’s Common Stock, at a ratio to be determined by the Company’s Board of Directors in the range of one-for-two (1-for-2) through one-for-one hundred (1-for-100), by voting as follows: For Against Abstain 27,379,571 1,761,895 157,711”

HeartSciences Inc. shareholders approved Election of Directors at the 2024-01-17 meeting.

“Proposal 1: Election of Directors Proposal The following two Class I nominees will serve for a three-year term expiring on the date of the Company’s 2026 Annual Meeting of Shareholders or until his successor is duly elected or his earlier resignation or removal, and the following two Class II nominees will serve for a three-year term expiring on the date of the Company’s 2027 Annual Meeting of Shareholders or until his successor is duly elected or his earlier resignation or removal. The voting with respect to the election of directors was as follows: Class I Directors Nominee Votes For Withheld Broker Non-Votes Brian Szymczak 22,817,292 437,448 6,044,437 Bruce Bent 22,800,131 454,609 6,044,437 Class II Directors Nominee Votes For Withheld Broker Non-Votes Mark Hilz 22,877,208 377,532 6,044,437 David R. Wells 22,814,389 440,351 6,044,437”

HeartSciences Inc. reported the second quarter fiscal 2024 ended October 31, 2023 results: revenue There were no significant revenues.

“Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.”

HeartSciences Inc. amended Amended EDA with Maxim Group LLC valued at up to $10,000,000 (effective 2023-11-09).

“On November 9, 2023, the Company entered into Amendment No. 1 to the Original EDA (the “Amended EDA” and together with the Original EDA, the “EDA”) with Maxim Group pursuant to which the Company may issue and sell up to $10,000,000 of its shares of Common Stock”

HeartSciences Inc. entered into Equity Distribution Agreement with Maxim Group LLC valued at up to $3,250,000 (effective 2023-09-18).

“On September 18, 2023, Heart Test Laboratories, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim Group”) as sales agent, pursuant to which the Company may offer and sell, from time to time, an aggregate of up to $3,250,000 of its shares of common stock, $0.001 par value per share (the “Shares”), in an “at the market offering””

HeartSciences Inc. entered into Securities Purchase Agreement with Icahn School of Medicine at Mount Sinai (effective 2023-09-20).

“on September 20, 2023, the Company and Mount Sinai entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement”), pursuant to which the Company agreed to sell to Mount Sinai as of the Closing Date (as defined below)”

HeartSciences Inc. entered into License Agreements with Icahn School of Medicine at Mount Sinai (effective 2023-09-20).

“On September 20, 2023, Heart Test Laboratories, Inc. (the “Company”) entered into several definitive license agreements (each a “License Agreement” and collectively, the “License Agreements”) with Icahn School of Medicine at Mount Sinai (“Mount Sinai”).”

HeartSciences Inc. reported the first quarter fiscal 2024 ended July 31, 2023 results: revenue There were no revenues.

“HeartSciences Reports First Quarter Fiscal 2024 Financial Results”

HeartSciences Inc. incurred loan of up to $1,000,000 with Matthews Southwest Holdings, Inc. at no interest, except upon an event of default, at which time, interest accrues at maturing December 31, 2023.

“Unsecured Promissory Drawdown Loan Note (the "MSW Note") with Matthews Southwest Holdings, Inc. (the "Lender"). The MSW Note provides for an unsecured drawdown loan of up to $1,000,000, drawn in installments consisting of (i) $250,000 on or prior to September 8, 2023, (ii) $250,000 on or prior to September 20, 2023, and (iii) further drawdowns of up to $500,000”

HeartSciences Inc. entered into Senior Unsecured Promissory Drawdown Loan Note with Matthews Southwest Holdings, Inc. valued at up to $1,000,000 unsecured drawdown loan, issued in installments: $250,000 on or prior to September (effective 2023-09-07).

“On September 7, 2023, Heart Test Laboratories, Inc. (the "Company") entered into a Senior Unsecured Promissory Drawdown Loan Note (the "MSW Note") with Matthews Southwest Holdings, Inc. (the "Lender").”

HeartSciences Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 1, 2023, the Staff notified the Company that the bid price of its common stock failed to close above the minimum $1 requirement for the past 30 trading days, pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Company attended an August 17, 2023, hearing before the Panel and requested the continued listing of its securities on the Nasdaq Capital Market pending its return to compliance with the Equity Rule and the Bid Price Rule. On August 28, 2023, the Company received a decision from the Panel granting the Company’s request for continued listing on the Nasdaq Capital”

HeartSciences Inc. received a nasdaq hearing update notice regarding stockholders equity (rules 5250(b)(1)).

“August 28, 2023, the Company received a decision from the Panel granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with the Equity Rule on or before November 21, 2023, and certain other conditions. In addition, The Company has until January 29, 2024, to demonstrate compliance with the minimum $1 bid price requirement pursuant to the Bid Price Rule. Statements contained herein relating to the Company or its management’s intentions, hopes, beliefs, expectations or predictions of the future, including, but not limited”

HeartSciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 2, 2023, Heart Test Laboratories, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, based on the closing bid price for the previous 30 consecutive business days, the listing of the Company’s shares of common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”). The letter from Nasdaq has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In accor”

HeartSciences Inc. reported financial results for fiscal year ended April 30, 2023.

“Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the fiscal year ended April 30, 2023.”

HeartSciences Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“June 20, 2023, the Company received a delist determination letter from the Staff advising the Company that the Staff had determined that the Company did not meet the terms of the extension by the June 19, 2023 deadline. The Company intends to timely appeal the Staff's delisting determination by submitting a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request will automatically stay the delisting of the Company's securities by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to”

HeartSciences Inc. reported the fiscal 2023 third quarter ended January 31, 2023 results: revenue no meaningful revenues.

“Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023.”

HeartSciences Inc. entered into purchase agreement with Lincoln Park Capital Fund, LLC valued at up to $15.0 million (effective 2023-03-10).

“On March 10, 2023, Heart Test Laboratories, Inc. (the "Company") entered into a purchase agreement and a registration rights agreement with an institutional investor, Lincoln Park Capital Fund, LLC ("Lincoln Park"), an Illinois limited liability company, providing for the purchase of up to $15.0 million worth of the Company's common stock, par value $0.001 per share, over the thirty-six month term of the purchase agreement.”

HeartSciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 8, 2023, the Company received a letter from Nasdaq in which it stated, that based on the Company's submission of its plan of compliance to Nasdaq, Nasdaq has determined to grant the Company an extension of time to regain compliance with Nasdaq Listing Rule 5550(b)(1) until June 19, 2023. The Company must furnish to the SEC and Nasdaq a publicly available report (e.g. a Form 8-K) which report, among other things, includes a description of the completed transaction or event that enabled the Company to satisfy the stockholders' equity requirement for continued listing. After filing the p”

HeartSciences Inc. amended Amendment No. 2 to the Bridge Warrants with the lead investor under the SPA valued at Amendment to Bridge Warrants reducing exercise price to $1.00 for limited period (Feb 3-16, 2023), a (effective 2023-02-03).

“On February 3, 2023, Heart Test Laboratories, Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the warrants to purchase shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), issued in the Company’s private placement of securities pursuant to that certain Securities Purchase Agreement dated as of December 22, 2021 (the “SPA,” and such warrants issued thereunder, as previously amended on September 8, 2022, the “Bridge Warrants”).”

HeartSciences Inc. amended Amendment No. 4 with Front Range Ventures LLC and John Q. Adams valued at $1.2 million (effective 2023-01-24).

“On January 24, 2023, Heart Test Laboratories, Inc. (the “Company”) entered into Amendment No. 4 (the “Amendment”) to the Loan and Security Agreement dated April 24, 2020 (the “Agreement”) by and among the Company, Front Range Ventures LLC (“FRV”) and John Q. Adams (“Adams”) which was previously amended on September 30, 2021, November 3, 2021 and May 24, 2022.”

David R. Wells was appointed as Director at HeartSciences Inc..

“Effective December 28, 2022, the Board appointed David R. Wells to the Board as a director to fill the vacancy created by Mr. Kanouff’s resignation.”

Patrick Kanouff resigned as Director at HeartSciences Inc..

“Effective December 27, 2022, Patrick Kanouff voluntarily resigned from the Board of Directors (the “Board”) of Heart Test Laboratories, Inc. (the “Company”).”

HeartSciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 21, 2022, Heart Test Laboratories, Inc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its quarterly report for the period ended October 31, 2022, the Company reported stockholders’ equity of $1,082,676, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the Com”

HeartSciences Inc. reported financial results for the fiscal 2023 second quarter ended October 31, 2022.

“On December 16, 2022, Heart Test Laboratories, Inc. (the "Company") issued a press release providing information regarding the Company's financial and operating results for the quarter ended October 31, 2022, and other business updates.”